These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
150 related articles for article (PubMed ID: 22182499)
1. Facile synthesis of tetracyclic azepine and oxazocine derivatives and their potential as MAPKAP-K2 (MK2) inhibitors. Rao AU; Xiao D; Huang X; Zhou W; Fossetta J; Lundell D; Tian F; Trivedi P; Aslanian R; Palani A Bioorg Med Chem Lett; 2012 Jan; 22(2):1068-72. PubMed ID: 22182499 [TBL] [Abstract][Full Text] [Related]
2. In vivo and in vitro SAR of tetracyclic MAPKAP-K2 (MK2) inhibitors. Part II. Revesz L; Schlapbach A; Aichholz R; Dawson J; Feifel R; Hawtin S; Littlewood-Evans A; Koch G; Kroemer M; Möbitz H; Scheufler C; Velcicky J; Huppertz C Bioorg Med Chem Lett; 2010 Aug; 20(15):4719-23. PubMed ID: 20591669 [TBL] [Abstract][Full Text] [Related]
3. 2,4-Diaminopyrimidine MK2 inhibitors. Part I: Observation of an unexpected inhibitor binding mode. Argiriadi MA; Ericsson AM; Harris CM; Banach DL; Borhani DW; Calderwood DJ; Demers MD; Dimauro J; Dixon RW; Hardman J; Kwak S; Li B; Mankovich JA; Marcotte D; Mullen KD; Ni B; Pietras M; Sadhukhan R; Sousa S; Tomlinson MJ; Wang L; Xiang T; Talanian RV Bioorg Med Chem Lett; 2010 Jan; 20(1):330-3. PubMed ID: 19919896 [TBL] [Abstract][Full Text] [Related]
4. Structure-based lead identification of ATP-competitive MK2 inhibitors. Barf T; Kaptein A; de Wilde S; van der Heijden R; van Someren R; Demont D; Schultz-Fademrecht C; Versteegh J; van Zeeland M; Seegers N; Kazemier B; van de Kar B; van Hoek M; de Roos J; Klop H; Smeets R; Hofstra C; Hornberg J; Oubrie A Bioorg Med Chem Lett; 2011 Jun; 21(12):3818-22. PubMed ID: 21565500 [TBL] [Abstract][Full Text] [Related]
5. The discovery of carboline analogs as potent MAPKAP-K2 inhibitors. Wu JP; Wang J; Abeywardane A; Andersen D; Emmanuel M; Gautschi E; Goldberg DR; Kashem MA; Lukas S; Mao W; Martin L; Morwick T; Moss N; Pargellis C; Patel UR; Patnaude L; Peet GW; Skow D; Snow RJ; Ward Y; Werneburg B; White A Bioorg Med Chem Lett; 2007 Aug; 17(16):4664-9. PubMed ID: 17576063 [TBL] [Abstract][Full Text] [Related]
6. Tricyclic azepine derivatives: pyrimido[4,5-b]-1,4-benzoxazepines as a novel class of epidermal growth factor receptor kinase inhibitors. Smith L; Piatnitski EL; Kiselyov AS; Ouyang X; Chen X; Burdzovic-Wizemann S; Xu Y; Pan W; Chen X; Wang Y; Rosler RL; Patel SN; Chiang HH; Milligan DL; Columbus J; Wong WC; Doody JF; Hadari YR Bioorg Med Chem Lett; 2006 Mar; 16(6):1643-6. PubMed ID: 16412636 [TBL] [Abstract][Full Text] [Related]
7. Conformation constraint of anilides enabling the discovery of tricyclic lactams as potent MK2 non-ATP competitive inhibitors. Xiao D; Palani A; Huang X; Sofolarides M; Zhou W; Chen X; Aslanian R; Guo Z; Fossetta J; Tian F; Trivedi P; Spacciapoli P; Whitehurst CE; Lundell D Bioorg Med Chem Lett; 2013 Jun; 23(11):3262-6. PubMed ID: 23602398 [TBL] [Abstract][Full Text] [Related]
8. Structural analysis of an MK2-inhibitor complex: insight into the regulation of the secondary structure of the Gly-rich loop by TEI-I01800. Fujino A; Fukushima K; Namiki N; Kosugi T; Takimoto-Kamimura M Acta Crystallogr D Biol Crystallogr; 2010 Jan; 66(Pt 1):80-7. PubMed ID: 20057052 [TBL] [Abstract][Full Text] [Related]
9. In vivo and in vitro SAR of tetracyclic MAPKAP-K2 (MK2) inhibitors. Part I. Revesz L; Schlapbach A; Aichholz R; Feifel R; Hawtin S; Heng R; Hiestand P; Jahnke W; Koch G; Kroemer M; Möbitz H; Scheufler C; Velcicky J; Huppertz C Bioorg Med Chem Lett; 2010 Aug; 20(15):4715-8. PubMed ID: 20594847 [TBL] [Abstract][Full Text] [Related]
10. Design and synthesis of benzoazepin-2-one analogs as allosteric binders targeting the PIF pocket of PDK1. Wei L; Gao X; Warne R; Hao X; Bussiere D; Gu XJ; Uno T; Liu Y Bioorg Med Chem Lett; 2010 Jul; 20(13):3897-902. PubMed ID: 20627557 [TBL] [Abstract][Full Text] [Related]
11. Discovery of selective and orally available spiro-3-piperidyl ATP-competitive MK2 inhibitors. Kaptein A; Oubrie A; de Zwart E; Hoogenboom N; de Wit J; van de Kar B; van Hoek M; Vogel G; de Kimpe V; Schultz-Fademrecht C; Borsboom J; van Zeeland M; Versteegh J; Kazemier B; de Roos J; Wijnands F; Dulos J; Jaeger M; Leandro-Garcia P; Barf T Bioorg Med Chem Lett; 2011 Jun; 21(12):3823-7. PubMed ID: 21565498 [TBL] [Abstract][Full Text] [Related]
12. 4-Anilino-6-phenyl-quinoline inhibitors of mitogen activated protein kinase-activated protein kinase 2 (MK2). Olsson H; Sjö P; Ersoy O; Kristoffersson A; Larsson J; Nordén B Bioorg Med Chem Lett; 2010 Aug; 20(16):4738-40. PubMed ID: 20643547 [TBL] [Abstract][Full Text] [Related]
13. Pyrazinoindolone inhibitors of MAPKAP-K2. Goldberg DR; Choi Y; Cogan D; Corson M; DeLeon R; Gao A; Gruenbaum L; Hao MH; Joseph D; Kashem MA; Miller C; Moss N; Netherton MR; Pargellis CP; Pelletier J; Sellati R; Skow D; Torcellini C; Tseng YC; Wang J; Wasti R; Werneburg B; Wu JP; Xiong Z Bioorg Med Chem Lett; 2008 Feb; 18(3):938-41. PubMed ID: 18221871 [TBL] [Abstract][Full Text] [Related]
14. Discovery of a novel series of potent MK2 non-ATP competitive inhibitors using 1,2-substituted azoles as cis-amide isosteres. Xiao D; Zhu X; Sofolarides M; Degrado S; Shao N; Rao A; Chen X; Aslanian R; Fossetta J; Tian F; Trivedi P; Lundell D; Palani A Bioorg Med Chem Lett; 2014 Aug; 24(15):3609-13. PubMed ID: 24913714 [TBL] [Abstract][Full Text] [Related]
15. A three-step protocol for lead optimization: quick identification of key conformational features and functional groups in the SAR studies of non-ATP competitive MK2 (MAPKAPK2) inhibitors. Huang X; Zhu X; Chen X; Zhou W; Xiao D; Degrado S; Aslanian R; Fossetta J; Lundell D; Tian F; Trivedi P; Palani A Bioorg Med Chem Lett; 2012 Jan; 22(1):65-70. PubMed ID: 22169260 [TBL] [Abstract][Full Text] [Related]
16. Identification of novel, potent and selective inhibitors of Polo-like kinase 1. Chen S; Bartkovitz D; Cai J; Chen Y; Chen Z; Chu XJ; Le K; Le NT; Luk KC; Mischke S; Naderi-Oboodi G; Boylan JF; Nevins T; Qing W; Chen Y; Wovkulich PM Bioorg Med Chem Lett; 2012 Jan; 22(2):1247-50. PubMed ID: 22172702 [TBL] [Abstract][Full Text] [Related]
17. Design and synthesis of Rho kinase inhibitors (II). Iwakubo M; Takami A; Okada Y; Kawata T; Tagami Y; Ohashi H; Sato M; Sugiyama T; Fukushima K; Iijima H Bioorg Med Chem; 2007 Jan; 15(1):350-64. PubMed ID: 17046269 [TBL] [Abstract][Full Text] [Related]
18. 2,4-Diaminopyrimidine MK2 inhibitors. Part II: Structure-based inhibitor optimization. Harris CM; Ericsson AM; Argiriadi MA; Barberis C; Borhani DW; Burchat A; Calderwood DJ; Cunha GA; Dixon RW; Frank KE; Johnson EF; Kamens J; Kwak S; Li B; Mullen KD; Perron DC; Wang L; Wishart N; Wu X; Zhang X; Zmetra TR; Talanian RV Bioorg Med Chem Lett; 2010 Jan; 20(1):334-7. PubMed ID: 19926477 [TBL] [Abstract][Full Text] [Related]
19. Mitogen-activated protein kinase-activated protein kinase 2 (MAPKAP-K2) as an antiinflammatory target: discovery and in vivo activity of selective pyrazolo[1,5-a]pyrimidine inhibitors using a focused library and structure-based optimization approach. Kosugi T; Mitchell DR; Fujino A; Imai M; Kambe M; Kobayashi S; Makino H; Matsueda Y; Oue Y; Komatsu K; Imaizumi K; Sakai Y; Sugiura S; Takenouchi O; Unoki G; Yamakoshi Y; Cunliffe V; Frearson J; Gordon R; Harris CJ; Kalloo-Hosein H; Le J; Patel G; Simpson DJ; Sherborne B; Thomas PS; Suzuki N; Takimoto-Kamimura M; Kataoka K J Med Chem; 2012 Aug; 55(15):6700-15. PubMed ID: 22746295 [TBL] [Abstract][Full Text] [Related]
20. Discovery and initial SAR of inhibitors of interleukin-1 receptor-associated kinase-4. Powers JP; Li S; Jaen JC; Liu J; Walker NP; Wang Z; Wesche H Bioorg Med Chem Lett; 2006 Jun; 16(11):2842-5. PubMed ID: 16563752 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]